Physician profile
Paul Dente
NPI 1992187256
$6,831.45
in general payments reported to CMS, 2019-2025
16 companies · $6,712 in 2025
The $6,712 reported for 2025 was more than what 98% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.58 · 2022: $32.15 · 2024: $67.16 · 2025: $6,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $1,342 · Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $1,342.17 |
| Food and Beverage | $936.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,842.17 | 2025 | |
| Mayne Pharma Commercial LLC | $245.27 | 2025 | |
| Biogen, INC. | $146.37 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $136.96 | 2025 | Gemtesa, Myfembree |
| Evofem Biosciences, INC. | $91.71 | 2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $74.82 | 2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Sanara Medtech INC. | $67.16 | 2024 | Celleraterx |
| Pharming Healthcare, INC. | $53.34 | 2025 | Ruconest |
| Becton, Dickinson and Company | $32.15 | 2022 | |
| Abbvie INC. | $30.12 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.47 | 2025 | Exparel |
| Organon LLC | $21.47 | 2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $20.58 | 2019 | |
| Exact Sciences Corporation | $16.15 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $15.99 | 2025 | Paragard T 380a |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $14.72 | 2025 | Intrarosa, Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.